Markets

Insider Trading

Hedge Funds

Retirement

Opinion

10 Best Health Insurance Stocks to Buy

Page 1 of 6

In this article, we list the 10 best health insurance stocks to buy.

The Healthcare Market: What does the future hold?

2023 posed significant challenges for the healthcare sector as investors adjusted their portfolios to adapt to a higher interest rate environment. This led to the sector underperforming compared to other segments of the equity market, particularly technology and communication services. The disruptive environment has understandably created some anxiety and pessimism about the future. Deloitte’s annual Health Care Outlook Survey reveals that only 3% of health system executives and 7% of health plan executives have a “positive” outlook for 2024, down from 15% and 40%, respectively, marking a significant year-over-year decline.

On the brighter side, the aging baby boomer generation, which constitutes 20% of the U.S. population, is driving a growing demand for healthcare services and products such as insurance, pharmaceuticals, medical devices, and hospital care. Projections indicate a notable increase in healthcare spending over the next decade. In the U.S., the Centers for Medicare & Medicaid Services forecasts a 5.6% annual growth in national health expenditure between 2023 and 2032. Similarly, in OECD countries, healthcare spending as a percentage of GDP is expected to rise from 8.8% to 10.2% by 2030. Alongside aging populations, the expanding middle class in emerging markets will also contribute to heightened demand for healthcare services.

One of the biggest news stories of the year was the rise of GLP-1 drugs as weight loss treatments, leading to significant outperformance by leading developers Eli Lilly & Company and Novo Nordisk (NVO) compared to their peers. Conversely, many companies experienced a severe downturn due to the post-COVID revenue drop, after vaccine and therapeutic sales neared $100 billion in 2022, resulting in challenging year-over-year comparisons. On another front, BlackRock, Inc. projects that the healthcare sector will have the highest 12-month forward earnings growth across all sectors on a year-on-year basis, with sales growth trailing only the consumer discretionary and information technology sectors.

The State of Health Insurance

Health insurance remains a prominent issue, especially in the United States. In 2022, over 300 million Americans, approximately 92% of the population, had health insurance. While the U.S. healthcare system features a blend of public and private insurers, private insurance comes out on top as the predominant form of coverage. That same year, more than half of insured individuals received private insurance through their employer, while approximately 36% were covered by public insurance programs like Medicare and Medicaid.

As of 2023, the US health insurance exchanges, created under the Affordable Care Act in 2014, market their tenth year of operation. Throughout this decade, the individual market has remained interesting, to say the least, having experienced annual fluctuations in insurer participation, pricing, and plan options. According to McKinsey, consumer engagement significantly increased by 25% from 2020 to 2022, reaching approximately 16 million participants, thus aligning with the enhanced subsidies introduced by the American Rescue Plan Act of 2021.

The global health insurance industry is poised for substantial growth in the coming years. According to a report, the global health insurance market is projected to achieve a Compound Annual Growth Rate (CAGR) of 9.9% from 2022 to 2030, reaching a market value of $5.28 trillion by 2030.

Insurance house, car and family health live concept. The insurance agent presents the toys that symbolize the coverage.

Our Methodology

To compile our list of the best health insurance stocks to buy, we sifted through multiple ETFs and internet rankings. We then analyzed Insider Monkey’s Q1 2024 database to select the stocks that were the most widely held by hedge funds. The following companies, ranked by the number of hedge funds holding their shares, provide health insurance services within the United States and/or internationally. Why do we care about what hedge funds do? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (see more details here).

10 Best Health Insurance Stocks to Buy

10. MetLife, Inc. (NYSE:MET)

Number of Hedge Fund Holders: 36

The Metropolitan Life Insurance Company, widely known as MetLife Inc. (NYSE:MET), stands as one of the world’s largest providers of insurance, annuities, and employee benefit programs, serving over 90 million customers across more than 60 countries.

Recently, MetLife Inc. (NYSE:MET) announced a substantial increase in its share repurchase authorization to $3 billion, reflecting a strong first quarter in 2024. The company reported a 20% year-over-year rise in adjusted earnings, reaching $1.3 billion or $1.83 per share. Adjusted premium fees and other revenues totaled $12 billion, marking a 4% growth compared to the same quarter the previous year.

Piper Sandler revised its outlook on MetLife Inc. (NYSE:MET) shares, lowering the price target to $82 from $85 while maintaining an Overweight rating. This adjustment follows an increase in Group Benefits claims, particularly in dental, a trend observed industry-wide this earnings season. Piper Sandler noted that excluding the impact of these heightened claims, MetLife Inc. (NYSE:MET)’s earnings were consistent with projections.

Hedge fund sentiment towards MetLife Inc. (NYSE:MET) appears positive, with 36 funds holding significant stakes in the company as of Q1 2024. The hedge fund with the largest position in MET is Richard S. Pzena’s Pzena Investment Management.

9. Chubb Limited (NYSE:CB)

Number of Hedge Fund Holders: 53

Chubb Limited (NYSE:CB) is a global insurance corporation offering a wide range of insurance and reinsurance products to individuals, businesses, and other entities worldwide. In the first quarter, the company reported robust financial results, surpassing analyst expectations with earnings per share of $5.41, which was $0.10 higher than the consensus estimate of $5.31. Chubb’s revenue reached $12.22 billion, exceeding the analyst forecast of $11.75 billion. Despite the positive results, the stock traded flat after-hours.

The insurer also reported a 13.3% increase in net income to $2.14 billion and a 20.3% rise in core operating income to $2.22 billion. These improvements were partially influenced by two one-time items: a $55 million deferred tax benefit related to Bermuda tax law and a $30 million contribution to the Chubb Charitable Foundation.

Additionally, Warren Buffett’s Berkshire Hathaway revealed a significant investment in Chubb Limited (NYSE:CB). The conglomerate purchased nearly 26 million shares of the Zurich-based insurer, a stake worth $6.7 billion, making it Berkshire’s ninth-largest holding as of the end of March. Following the news of Berkshire’s investment, shares of Chubb Limited (NYSE:CB) jumped nearly 7% in extended trading. The stock has gained approximately 16.5% year to date.

Out of the 919 hedge funds tracked by Insider Monkey, 53 reported owning stock in Chubb Limited (NYSE:CB) as of Q1 2024. Millennium Management was among the leading hedge fund investors in the company, with a stake worth over $54.9 million

8. CVS Health Corporation (NYSE:CVS)

Number of Hedge Fund Holders: 54

CVS Health Corporation (NYSE:CVS) is a U.S.-based healthcare enterprise that manages an extensive network of retail pharmacies and clinics across the country. The corporation oversees various brands, including CVS Pharmacy, a retail pharmacy chain; CVS Caremark, a pharmacy benefits manager; and Aetna, a health insurance provider.

In early May, Argus revised its stock price target for CVS Health Corporation (NYSE:CVS), lowering it to $80 from the previous $100 while maintaining a Buy rating. This adjustment followed CVS Health’s first-quarter earnings for 2024, which fell short of market expectations and led the company to revise its guidance downward. The new earnings per share forecast for 2024 is set at “at least $7.00,” down from the “at least $8.30” projected in February and the “at least $8.50” anticipated during the Investor Day in December.

The company experienced higher-than-anticipated usage in the Medicare Advantage plans offered through its Health Care Benefits segment. As a result, CVS now projects its adjusted operating income for 2024 to be at least $14.75 billion, down from the $16.9 billion estimate provided in February and the initial $17.24 billion outlook from December.

Additionally, on May 23, CVS Health Corporation (NYSE:CVS) saw its shares decline by as much as 3% following an unconfirmed report that the company was seeking a private equity (PE) partnership to expand its Oak Street Health platform. According to the report, CVS Health Corporation (NYSE:CVS) may pursue a partnership similar to Humana’s with Welsh Carson, where CVS would initially take a minority interest in new clinics with an option to purchase once they are established. Analysts and RBC Capital Markets, however, believe that Oak Street clinics will reach break-even by year three or four and mature with $6-7 million in clinic-level profit by year six, protecting CVS from startup losses during the clinics’ early years.

Ariel Global Fund stated the following regarding CVS Health Corporation (NYSE:CVS) in its first quarter 2024 investor letter:

“We bought American healthcare company, CVS Health Corporation (NYSE:CVS), following recent concerns related to potential new laws affecting Pharmacy Benefit Managers (PBMs)—intermediaries that negotiate drug prices between insurers and pharmacies—and issues with pricing in its Medicare Advantage plans, a type of health insurance for senior citizens. Shares presented an attractive entry point after the company lowered its 2024 outlook. While investor apprehension regarding the new laws appears to have eased, utilization of Medicare Advantage plans is also stabilizing. Our purchase of CVS reflects our efforts to capitalize on temporary setbacks and secure positions in companies poised for a rebound.”

7. Centene Corporation (NYSE:CNC)

Number of Hedge Fund Holders: 56

Centene Corporation (NYSE:CNC), based in St. Louis, Missouri, is a publicly traded managed care firm that acts as an intermediary for both government-sponsored and privately insured healthcare programs. The company primarily focuses on the Medicaid market, with a significant portion of its membership coming from programs like the Children’s Health Insurance Program (CHIP) and Temporary Assistance for Needy Families (TANF).

Centene Corporation (NYSE:CNC) reported first-quarter profits of $1.1 billion, driven by an increase in membership and premium revenue, thanks to a significant rise in Obamacare enrollment. The company’s net income exceeded Wall Street analysts’ expectations, reaching $1.16 billion, or $2.16 per share, compared to $1.13 billion, or $2.04 per share, in the same quarter last year, while total revenue increased to $40.4 billion from $38.9 billion year-over-year.

Centene Corporation (NYSE:CNC) also raised its 2024 diluted earnings per share guidance floor to more than $5.94 and its adjusted diluted EPS guidance floor to more than $6.80. The growth in the commercial marketplace, particularly Obamacare, contributed to a 4% increase in “premium and service revenues,” which rose to $36.3 billion from $35.0 billion in the first quarter of 2023.

Among the largest hedge fund shareholders of Centene Corporation (NYSE:CNC) is Harris Associates, holding shares valued at $1.33 billion.

Oakmark Global Fund stated the following regarding Centene Corporation (NYSE:CNC) in its first quarter 2024 investor letter:

Centene Corporation (NYSE:CNC) is a large health insurer specializing in three major government-sponsored programs: Medicaid, Marketplace and Medicare Advantage. Each of these programs benefits from long-term secular tailwinds. In Medicaid, states are steadily outsourcing their programs to managed care companies like Centene to help reduce costs and improve care quality. Managed Medicaid penetration has increased meaningfully over the past two decades, and we expect further gains over time. In Marketplace, growth is driven by the trend toward more individuals buying health insurance. Centene holds the top market share in both of these programs and is well-positioned to capitalize on their continued growth. Finally, in Centene’s Medicare Advantage business, past missteps will result in losses next year, but we believe Centene can turn its Medicare Advantage segment around and generate positive earnings in the next few years. Centene currently trades for about 9x our estimate of normal earnings power, which we believe is a compelling value for a business that generates healthy returns on capital and is capable of growing EPS at a low double-digit rate.”

6. The Cigna Group (NYSE:CI)

Number of Hedge Fund Holders: 61

The Cigna Group (NYSE:CI) and its subsidiaries specialize in offering insurance and related products and services in the United States. The company also provides pharmacy benefits, home delivery pharmacy, and specialty pharmacy distribution services.

The Cigna Group (NYSE:CI) reported a notable first-quarter, with sales of $57.26 billion, a 23% year-over-year increase, surpassing the consensus estimate of $55.47 billion. This growth was primarily driven by substantial gains in Evernorth Health Services, reflecting multiple large client acquisitions. Adjusted income from operations rose 16% to $1.88 billion, with strong contributions from both Cigna Healthcare and Evernorth Health Services. Cigna Healthcare sales increased 4% year-over-year to $13.3 billion, reflecting premium rate adjustments.

Following The Cigna Group (NYSE:CI)’s strong first-quarter financial results, RBC Capital Markets slightly raised its price target for CI shares to $384 from $383, while maintaining an Outperform rating. RBC’s assessment was also influenced by Cigna’s recent investor day, during which the company raised its long-term growth targets to a range of 10-14%, a projection RBC believes is justified based on The Cigna Group (NYSE:CI)’s current performance and trajectory.

Hedge fund sentiment towards The Cigna Group (NYSE:CI) appears positive, with 61 funds holding significant stakes in the company as of Q1 2024. The largest position is held by Glenview Capital, which owns 1.47 million shares valued at $534.3 million.

Here is what Davis New York Venture Fund has to say about The Cigna Group (NYSE:CI) in its Q3 2023 investor letter:

“In the attractive healthcare sector, we look beyond the obvious to identify businesses that simultaneously have exposure to this growth industry and also trade at low prices. We’re especially drawn to companies like Cigna Group, whose products or services play a part in helping to mitigate healthcare’s constantly rising costs. The healthcare industry has been a growing part of the U.S. economy for decades. As a result, many companies in this sector trade at high valuations reflecting their robust but well-known reputation for growth. For value-conscious investors like us, investing in healthcare requires looking beyond the obvious to identify businesses that have exposure to this growth industry but which trade at low prices. Furthermore, recognizing that the constantly rising cost of healthcare cannot go on forever, we have been particularly drawn to companies whose products or services play some role in managing or reducing the cost of care. As a result, we have positions in Cigna Group, a well-regarded provider of managed care.

Page 1 of 6

AI Fire Sale: Insider Monkey’s #1 AI Stock Pick Is On A Steep Discount

Artificial intelligence is the greatest investment opportunity of our lifetime. The time to invest in groundbreaking AI is now, and this stock is a steal!

The whispers are turning into roars.

Artificial intelligence isn’t science fiction anymore.

It’s the revolution reshaping every industry on the planet.

From driverless cars to medical breakthroughs, AI is on the cusp of a global explosion, and savvy investors stand to reap the rewards.

Here’s why this is the prime moment to jump on the AI bandwagon:

Exponential Growth on the Horizon: Forget linear growth – AI is poised for a hockey stick trajectory.

Imagine every sector, from healthcare to finance, infused with superhuman intelligence.

We’re talking disease prediction, hyper-personalized marketing, and automated logistics that streamline everything.

This isn’t a maybe – it’s an inevitability.

Early investors will be the ones positioned to ride the wave of this technological tsunami.

Ground Floor Opportunity: Remember the early days of the internet?

Those who saw the potential of tech giants back then are sitting pretty today.

AI is at a similar inflection point.

We’re not talking about established players – we’re talking about nimble startups with groundbreaking ideas and the potential to become the next Google or Amazon.

This is your chance to get in before the rockets take off!

Disruption is the New Name of the Game: Let’s face it, complacency breeds stagnation.

AI is the ultimate disruptor, and it’s shaking the foundations of traditional industries.

The companies that embrace AI will thrive, while the dinosaurs clinging to outdated methods will be left in the dust.

As an investor, you want to be on the side of the winners, and AI is the winning ticket.

The Talent Pool is Overflowing: The world’s brightest minds are flocking to AI.

From computer scientists to mathematicians, the next generation of innovators is pouring its energy into this field.

This influx of talent guarantees a constant stream of groundbreaking ideas and rapid advancements.

By investing in AI, you’re essentially backing the future.

The future is powered by artificial intelligence, and the time to invest is NOW.

Don’t be a spectator in this technological revolution.

Dive into the AI gold rush and watch your portfolio soar alongside the brightest minds of our generation.

This isn’t just about making money – it’s about being part of the future.

So, buckle up and get ready for the ride of your investment life!

Act Now and Unlock a Potential 10,000% Return: This AI Stock is a Diamond in the Rough (But Our Help is Key!)

The AI revolution is upon us, and savvy investors stand to make a fortune.

But with so many choices, how do you find the hidden gem – the company poised for explosive growth?

That’s where our expertise comes in.

We’ve got the answer, but there’s a twist…

Imagine an AI company so groundbreaking, so far ahead of the curve, that even if its stock price quadrupled today, it would still be considered ridiculously cheap.

That’s the potential you’re looking at. This isn’t just about a decent return – we’re talking about a 10,000% gain over the next decade!

Our research team has identified a hidden gem – an AI company with cutting-edge technology, massive potential, and a current stock price that screams opportunity.

This company boasts the most advanced technology in the AI sector, putting them leagues ahead of competitors.

It’s like having a race car on a go-kart track.

They have a strong possibility of cornering entire markets, becoming the undisputed leader in their field.

Here’s the catch (it’s a good one): To uncover this sleeping giant, you’ll need our exclusive intel.

We want to make sure none of our valued readers miss out on this groundbreaking opportunity!

That’s why we’re slashing the price of our Premium Readership Newsletter by a whopping 70%.

For a ridiculously low price of just $29, you can unlock a year’s worth of in-depth investment research and exclusive insights – that’s less than a single restaurant meal!

Here’s why this is a deal you can’t afford to pass up:

• Access to our Detailed Report on this Game-Changing AI Stock: Our in-depth report dives deep into our #1 AI stock’s groundbreaking technology and massive growth potential.

• 11 New Issues of Our Premium Readership Newsletter: You will also receive 11 new issues and at least one new stock pick per month from our monthly newsletter’s portfolio over the next 12 months. These stocks are handpicked by our research director, Dr. Inan Dogan.

• One free upcoming issue of our 70+ page Quarterly Newsletter: A value of $149

• Bonus Reports: Premium access to members-only fund manager video interviews

• Ad-Free Browsing: Enjoy a year of investment research free from distracting banner and pop-up ads, allowing you to focus on uncovering the next big opportunity.

• 30-Day Money-Back Guarantee:  If you’re not absolutely satisfied with our service, we’ll provide a full refund within 30 days, no questions asked.

 

Space is Limited! Only 1000 spots are available for this exclusive offer. Don’t let this chance slip away – subscribe to our Premium Readership Newsletter today and unlock the potential for a life-changing investment.

Here’s what to do next:

1. Head over to our website and subscribe to our Premium Readership Newsletter for just $29.

2. Enjoy a year of ad-free browsing, exclusive access to our in-depth report on the revolutionary AI company, and the upcoming issues of our Premium Readership Newsletter over the next 12 months.

3. Sit back, relax, and know that you’re backed by our ironclad 30-day money-back guarantee.

Don’t miss out on this incredible opportunity! Subscribe now and take control of your AI investment future!


No worries about auto-renewals! Our 30-Day Money-Back Guarantee applies whether you’re joining us for the first time or renewing your subscription a year later!

A New Dawn is Coming to U.S. Stocks

I work for one of the largest independent financial publishers in the world – representing over 1 million people in 148 countries.

We’re independently funding today’s broadcast to address something on the mind of every investor in America right now…

Should I put my money in Artificial Intelligence?

Here to answer that for us… and give away his No. 1 free AI recommendation… is 50-year Wall Street titan, Marc Chaikin.

Marc’s been a trader, stockbroker, and analyst. He was the head of the options department at a major brokerage firm and is a sought-after expert for CNBC, Fox Business, Barron’s, and Yahoo! Finance…

But what Marc’s most known for is his award-winning stock-rating system. Which determines whether a stock could shoot sky-high in the next three to six months… or come crashing down.

That’s why Marc’s work appears in every Bloomberg and Reuters terminal on the planet…

And is still used by hundreds of banks, hedge funds, and brokerages to track the billions of dollars flowing in and out of stocks each day.

He’s used this system to survive nine bear markets… create three new indices for the Nasdaq… and even predict the brutal bear market of 2022, 90 days in advance.

Click to continue reading…